M

Mass General Brigham

Early-stage life science venture investor

RN Care Coordinator - Case Manager

Full-TimeDeadline 10/30/26
$41.71 - $105.65/hr+ Differentials + Premiums + Bonuses
Senior
Bachelor's
Boston, MA, USA
In Person
Medical, Clinical & Veterinary

About the job

Requirements
  • Graduate of an approved school of nursing with current registration in Massachusetts.
  • Newly licensed nurses must have a Bachelor of Science degree in Nursing.
  • At least 5 years of acute care experience is required.
  • At least 1 year of inpatient acute case management experience is required.
  • Bilingual English and Spanish is preferred.
  • Previous experience in a hospital or health care setting is required.
  • Strong clinical assessment skills are required.
  • Ability to work collaboratively and cooperatively within a team and with internal and external customers is required.
  • Strong organizational skills and ability to set priorities are required.
  • Ability to compile data from concurrent and retrospective medical record review to determine clinical appropriateness is required.
  • Ability to meet a patient’s needs based on their clinical diagnosis, level of care, and discharge plan is required.
  • Ability to negotiate several aspects of care coordination simultaneously is required.
  • Excellent written and verbal communication skills are required.
  • Must be flexible and able to work well independently.
Responsibilities
  • Manage a caseload of patients and ensure care supports desired clinical and financial outcomes.
  • Coordinate care prescribed by an interdisciplinary team, using patient assessment, care guidelines, protocols, payer regulations, and response to therapies to assess the episode of illness from pre-admission through post-discharge.
  • Participate in ongoing evaluation of practice patterns and systems and support efforts to improve quality, cost, and satisfaction outcomes.
  • Mobilize resources to maximize efficiency of care delivery.
  • Coordinate and ensure implementation of the plan of care using case management principles.
  • Develop a provisional treatment program and tentative discharge date before or within 24–48 hours of admission through interviews with patients or families and discussions with the physician team and other team members.
  • Review the daily treatment plan with physicians, nurses, and patients or families to ensure interdisciplinary communication and coordination.
  • Participate with nursing staff and physicians in patient care rounds to contribute to the plan of care and monitor and report patient progress.
  • Collaborate with other departments to expedite sequencing and scheduling of interventions, consultations, treatments, and ancillary services.
  • Provide daily continuity with patients to ensure needs related to discharge are met.
  • Incorporate utilization management principles and payer contracts into patient plans of care and inform physicians and nurses of their implications.
  • Present alternatives to inpatient stay to the attending physician, team, and patient or family based on assessed patient level of care and insurance benefits.
  • Seek assistance or consultation from Care Coordination leadership for outlier and potential or actual resource-intensive patients.
  • Interact with internal and external health care providers to facilitate patient care, including post-discharge services.
  • Contribute to the development, implementation, and monitoring of practice guidelines.
  • Identify attending, resident, and nurse learning needs related to case management and work with service leaders to develop an educational plan.
  • Coordinate and execute discharge planning for patients, ensuring each patient has a discharge plan.
  • Assess continuing care needs in conjunction with other caregivers.
  • Coordinate and schedule interdisciplinary meetings with the patient and family regarding discharge needs and plans, as appropriate.
  • Ensure patient education consistent with the discharge plan has occurred.
  • Identify service, treatment, and funding options for post-hospital care.
  • Promote interdisciplinary patient and family communications and documentation that facilitate discharge planning, striving to finalize plans the day before discharge.
  • Perform patient and family follow-up after discharge to monitor and support desired outcomes.
  • Initiate contact with home health agencies and extended care facilities to ensure prompt and effective transition of care.
  • Collaborate with appropriate individuals, departments, and payers to ensure the appropriateness of admission, continued stay, and reimbursement.
  • Identify patients likely to have unmet insurance and resource needs and communicate with or refer them to health care team members and other appropriate departments.
  • Communicate with third-party payers regarding patient progress with the treatment plan as needed.
  • Identify the need for and issue Medicare notices of non-coverage, documenting the process and communicating with patients or families and other members of the health care team.
  • Use industry-accepted utilization or medical management criteria, including InterQual, to identify, monitor, and report variances from the established treatment plan, including appropriateness of admission, continued stay, treatment delays, and discharge planning.
  • Conduct documented utilization reviews for insurers or intermediaries.
  • Identify SNF and AND days for Medicare and Medicaid patients.
  • Initiate concurrent actions to reduce or eliminate inappropriate hospital admissions and days, and system delays.
  • Work with payers and physicians to address level-of-care concerns concurrently that affect claims and reimbursement.
  • Contribute to utilization and practice improvement efforts by reviewing reports with colleagues and providing feedback on utilization trends and payer issues.
  • Serve as the primary patient information source for third-party payers.
Desired Qualifications
  • Bilingual English and Spanish is preferred.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.